Straits Times Index
3,426.47 -3.98 (-0.12%) Nikkei
37,667.41 -202.10 (-0.53%) Hang Seng
17,021.31 +16.34 (+0.10%) FTSE 100
8,285.71 +99.36 (+1.21%) BTC-USD
67,887.17 +2,210.70 (+3.37%) CMC Crypto 200
1,375.67 +45.07 (+3.39%)
Gilead Sciences, Inc. (GILD)
After hours:
| Previous close | 76.51 |
| Open | 76.03 |
| Bid | 76.99 x 300 |
| Ask | 77.05 x 500 |
| Day's range | 75.75 - 78.29 |
| 52-week range | 62.07 - 87.87 |
| Volume | |
| Avg. volume | 7,451,595 |
| Market cap | 95.943B |
| Beta (5Y monthly) | 0.20 |
| PE ratio (TTM) | 213.92 |
| EPS (TTM) | 0.36 |
| Earnings date | 08 Aug 2024 |
| Forward dividend & yield | 3.08 (4.02%) |
| Ex-dividend date | 14 Jun 2024 |
| 1y target est | 81.02 |
Business WireGilead Sciences to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024
FOSTER CITY, Calif., July 25, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2024 financial results and guidance will be released on Thursday, August 8, 2024, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s second quarter 2024 financial results and provide a business update.
Business WireGilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline
FOSTER CITY, Calif., July 25, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of key data from its innovative HIV treatment portfolio and research pipeline, including a broad range of investigational and marketed agents with varied dosing frequencies and administration methods. The findings presented at the 25th International AIDS Conference (AIDS 2024) reflect a portfolio and future-looking pipeline focused on person-centered drug development strategies to help addre
Business WireFull Efficacy and Safety Results for Gilead Investigational Twice-Yearly Lenacapavir for HIV Prevention Presented at AIDS 2024
FOSTER CITY, Calif., July 24, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced full efficacy and safety results from its pivotal, Phase 3 PURPOSE 1 trial. Detailed data from the trial’s interim analysis announced in June showed that lenacapavir, the company’s twice-yearly injectable HIV-1 capsid inhibitor, demonstrated zero infections, 100% efficacy and superiority to background HIV incidence for the investigational use of HIV prevention in cisgender women (women assigned female at bir
